The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery

Heng Jung Hsu, Tian Ya-Chung, Chen Yung-Chang, Lai Bien-Chieng, Fang Ji-Tsuen, Yang Chih Wei, Mai Szu Wu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. Sirolimus has been considered to be a non-nephrotoxic agent. It may delay graft function due to a potential hindrance of the recovery from acute tubular necrosis. It remains controversial as to whether the concomitant administration of sirolimus (SRL) with calcineurin inhibitors delays graft function in Asian patients. Method. This study enrolled 61 patients who received primary renal transplantation. Twenty-one patients aged 38.9 ± 11 years received early treatment with 6 mg/day sirolimus, 8 mg/kg/day cyclosporine (CsA) and prednisolone (SRL group). Forty patients with a mean age of 36.7 ± 9 years in the control group were treated with the standard immunosuppressive therapy (8 mg/kg/day CsA, mycophonolate mofetil and prednisolone). Results. The creatinine level at one week following transplantation in the SRL group was not significantly different from that in the control group (4.7 ± 1.0 versus 2.7 ± 0.4 mg/dL, p = 0.17). Similarly, there was no significant difference in the creatinine level at week 2 (3.4 ± 0.7 versus 2.7 ± 0.3 mg/dL, p = 0.36), week 3 (2.0 ± 0.3 versus 2.1 ± 0.2 mg/dL, p = 0.76), and week 4 (1.8 ± 0.2 versus 1.8±0.1 mg/dL, p = 0.92) between SRL and control groups, respectively. Similarly, the number of the patients with renal function impairment in both groups was not significantly different. The one-year patient and graft survival was 100% and 96%, respectively, in the SRL group and 100% and 98%, respectively, in the control group. Conclusion. The combination of sirolimus and cyclosporine did not prolong the recovery from transplantation-associated ischemic injury in kidney graft recipient. Our study demonstrated the safety of early usage of the concomitant administration of sirolimus and cyclosporine in kidney transplantation.

Original languageEnglish
Pages (from-to)303-306
Number of pages4
JournalRenal Failure
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

Recovery of Function
Sirolimus
Cyclosporine
Transplants
Kidney
Control Groups
Prednisolone
Kidney Transplantation
Creatinine
Transplantation
Graft Survival
Immunosuppressive Agents
Necrosis
Safety
Wounds and Injuries
Therapeutics

Keywords

  • Cyclosporine
  • Delayed graft function
  • Kidney transplantation
  • Sirolimus

ASJC Scopus subject areas

  • Nephrology

Cite this

Hsu, H. J., Ya-Chung, T., Yung-Chang, C., Bien-Chieng, L., Ji-Tsuen, F., Wei, Y. C., & Wu, M. S. (2008). The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery. Renal Failure, 30(3), 303-306. https://doi.org/10.1080/08860220701860989

The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery. / Hsu, Heng Jung; Ya-Chung, Tian; Yung-Chang, Chen; Bien-Chieng, Lai; Ji-Tsuen, Fang; Wei, Yang Chih; Wu, Mai Szu.

In: Renal Failure, Vol. 30, No. 3, 03.2008, p. 303-306.

Research output: Contribution to journalArticle

Hsu, HJ, Ya-Chung, T, Yung-Chang, C, Bien-Chieng, L, Ji-Tsuen, F, Wei, YC & Wu, MS 2008, 'The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery', Renal Failure, vol. 30, no. 3, pp. 303-306. https://doi.org/10.1080/08860220701860989
Hsu HJ, Ya-Chung T, Yung-Chang C, Bien-Chieng L, Ji-Tsuen F, Wei YC et al. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery. Renal Failure. 2008 Mar;30(3):303-306. https://doi.org/10.1080/08860220701860989
Hsu, Heng Jung ; Ya-Chung, Tian ; Yung-Chang, Chen ; Bien-Chieng, Lai ; Ji-Tsuen, Fang ; Wei, Yang Chih ; Wu, Mai Szu. / The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery. In: Renal Failure. 2008 ; Vol. 30, No. 3. pp. 303-306.
@article{4964f3efdc604fdfbf950582c3da9a02,
title = "The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery",
abstract = "Background. Sirolimus has been considered to be a non-nephrotoxic agent. It may delay graft function due to a potential hindrance of the recovery from acute tubular necrosis. It remains controversial as to whether the concomitant administration of sirolimus (SRL) with calcineurin inhibitors delays graft function in Asian patients. Method. This study enrolled 61 patients who received primary renal transplantation. Twenty-one patients aged 38.9 ± 11 years received early treatment with 6 mg/day sirolimus, 8 mg/kg/day cyclosporine (CsA) and prednisolone (SRL group). Forty patients with a mean age of 36.7 ± 9 years in the control group were treated with the standard immunosuppressive therapy (8 mg/kg/day CsA, mycophonolate mofetil and prednisolone). Results. The creatinine level at one week following transplantation in the SRL group was not significantly different from that in the control group (4.7 ± 1.0 versus 2.7 ± 0.4 mg/dL, p = 0.17). Similarly, there was no significant difference in the creatinine level at week 2 (3.4 ± 0.7 versus 2.7 ± 0.3 mg/dL, p = 0.36), week 3 (2.0 ± 0.3 versus 2.1 ± 0.2 mg/dL, p = 0.76), and week 4 (1.8 ± 0.2 versus 1.8±0.1 mg/dL, p = 0.92) between SRL and control groups, respectively. Similarly, the number of the patients with renal function impairment in both groups was not significantly different. The one-year patient and graft survival was 100{\%} and 96{\%}, respectively, in the SRL group and 100{\%} and 98{\%}, respectively, in the control group. Conclusion. The combination of sirolimus and cyclosporine did not prolong the recovery from transplantation-associated ischemic injury in kidney graft recipient. Our study demonstrated the safety of early usage of the concomitant administration of sirolimus and cyclosporine in kidney transplantation.",
keywords = "Cyclosporine, Delayed graft function, Kidney transplantation, Sirolimus",
author = "Hsu, {Heng Jung} and Tian Ya-Chung and Chen Yung-Chang and Lai Bien-Chieng and Fang Ji-Tsuen and Wei, {Yang Chih} and Wu, {Mai Szu}",
year = "2008",
month = "3",
doi = "10.1080/08860220701860989",
language = "English",
volume = "30",
pages = "303--306",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery

AU - Hsu, Heng Jung

AU - Ya-Chung, Tian

AU - Yung-Chang, Chen

AU - Bien-Chieng, Lai

AU - Ji-Tsuen, Fang

AU - Wei, Yang Chih

AU - Wu, Mai Szu

PY - 2008/3

Y1 - 2008/3

N2 - Background. Sirolimus has been considered to be a non-nephrotoxic agent. It may delay graft function due to a potential hindrance of the recovery from acute tubular necrosis. It remains controversial as to whether the concomitant administration of sirolimus (SRL) with calcineurin inhibitors delays graft function in Asian patients. Method. This study enrolled 61 patients who received primary renal transplantation. Twenty-one patients aged 38.9 ± 11 years received early treatment with 6 mg/day sirolimus, 8 mg/kg/day cyclosporine (CsA) and prednisolone (SRL group). Forty patients with a mean age of 36.7 ± 9 years in the control group were treated with the standard immunosuppressive therapy (8 mg/kg/day CsA, mycophonolate mofetil and prednisolone). Results. The creatinine level at one week following transplantation in the SRL group was not significantly different from that in the control group (4.7 ± 1.0 versus 2.7 ± 0.4 mg/dL, p = 0.17). Similarly, there was no significant difference in the creatinine level at week 2 (3.4 ± 0.7 versus 2.7 ± 0.3 mg/dL, p = 0.36), week 3 (2.0 ± 0.3 versus 2.1 ± 0.2 mg/dL, p = 0.76), and week 4 (1.8 ± 0.2 versus 1.8±0.1 mg/dL, p = 0.92) between SRL and control groups, respectively. Similarly, the number of the patients with renal function impairment in both groups was not significantly different. The one-year patient and graft survival was 100% and 96%, respectively, in the SRL group and 100% and 98%, respectively, in the control group. Conclusion. The combination of sirolimus and cyclosporine did not prolong the recovery from transplantation-associated ischemic injury in kidney graft recipient. Our study demonstrated the safety of early usage of the concomitant administration of sirolimus and cyclosporine in kidney transplantation.

AB - Background. Sirolimus has been considered to be a non-nephrotoxic agent. It may delay graft function due to a potential hindrance of the recovery from acute tubular necrosis. It remains controversial as to whether the concomitant administration of sirolimus (SRL) with calcineurin inhibitors delays graft function in Asian patients. Method. This study enrolled 61 patients who received primary renal transplantation. Twenty-one patients aged 38.9 ± 11 years received early treatment with 6 mg/day sirolimus, 8 mg/kg/day cyclosporine (CsA) and prednisolone (SRL group). Forty patients with a mean age of 36.7 ± 9 years in the control group were treated with the standard immunosuppressive therapy (8 mg/kg/day CsA, mycophonolate mofetil and prednisolone). Results. The creatinine level at one week following transplantation in the SRL group was not significantly different from that in the control group (4.7 ± 1.0 versus 2.7 ± 0.4 mg/dL, p = 0.17). Similarly, there was no significant difference in the creatinine level at week 2 (3.4 ± 0.7 versus 2.7 ± 0.3 mg/dL, p = 0.36), week 3 (2.0 ± 0.3 versus 2.1 ± 0.2 mg/dL, p = 0.76), and week 4 (1.8 ± 0.2 versus 1.8±0.1 mg/dL, p = 0.92) between SRL and control groups, respectively. Similarly, the number of the patients with renal function impairment in both groups was not significantly different. The one-year patient and graft survival was 100% and 96%, respectively, in the SRL group and 100% and 98%, respectively, in the control group. Conclusion. The combination of sirolimus and cyclosporine did not prolong the recovery from transplantation-associated ischemic injury in kidney graft recipient. Our study demonstrated the safety of early usage of the concomitant administration of sirolimus and cyclosporine in kidney transplantation.

KW - Cyclosporine

KW - Delayed graft function

KW - Kidney transplantation

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=41149123423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149123423&partnerID=8YFLogxK

U2 - 10.1080/08860220701860989

DO - 10.1080/08860220701860989

M3 - Article

VL - 30

SP - 303

EP - 306

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 3

ER -